Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
Cantor Fitzgerald
McKinsey
Boehringer Ingelheim
Chubb
Johnson and Johnson
Cerilliant
Fish and Richardson
Federal Trade Commission

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,344,011

« Back to Dashboard

Which drugs does patent 8,344,011 protect, and when does it expire?

Patent 8,344,011 protects VIBERZI and is included in one NDA.

This patent has fifty-eight patent family members in thirty-two countries.
Summary for Patent: 8,344,011
Title:Compounds as opioid receptor modulators
Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Inventor(s): Breslin; Henry J. (Lansdale, PA), Cai; Chaozhong (North Wales, PA), He; Wei (Audubon, PA), Kavash; Robert W. (Glenside, PA)
Assignee: Janssen Pharmaceutica, N.V. (Beerse, BE)
Application Number:12/838,825
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,344,011

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE). ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE). ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,344,011

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,741,356 Compounds as opioid receptor modulators ➤ Sign Up
8,772,325 Compounds as opioid receptor modulators ➤ Sign Up
9,205,076 Compounds as opioid receptor modulators ➤ Sign Up
9,700,542 Compounds as opioid receptor modulators ➤ Sign Up
7,786,158 Compounds as opioid receptor modulators ➤ Sign Up
8,609,709 Compounds as opioid receptor modulators ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,344,011

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I361069 ➤ Sign Up
Taiwan 200539876 ➤ Sign Up
Slovenia 2653465 ➤ Sign Up
Slovenia 2573068 ➤ Sign Up
Slovenia 2298744 ➤ Sign Up
Slovenia 1725537 ➤ Sign Up
Serbia 55122 ➤ Sign Up
Serbia 54199 ➤ Sign Up
Serbia 52933 ➤ Sign Up
Serbia 51995 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
US Army
Deloitte
Dow
Covington
Express Scripts
Teva
Boehringer Ingelheim
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot